Advertisement
Advertisement
U.S. markets open in 2 hours 53 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Amicus Therapeutics, Inc. (FOLD)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
7.74+0.26 (+3.48%)
At close: 04:00PM EDT
7.67 -0.07 (-0.90%)
After hours: 05:37PM EDT
Advertisement
Sign in to post a message.
  • C
    Chung
    Hello I'm new in bitcoin and i have been making huge losses but i recently see a lot of people earning from it. Can someone please tell me what I'm doing wrong
  • Y
    Yahoo Finance Insights
    Amicus Therapeutics reached a 52 Week low at 7.07
  • C
    Charlie
    JC keep on rolling, exercising 28000 options then selling stock
    YOUR THE BEST" !!!!!!
    Bearish
  • Y
    Yahoo Finance Insights
    Amicus Therapeutics reached a 52 Week low at 6.01
  • Y
    Yahoo Finance Insights
    Amicus Therapeutics reached a 52 Week low at 6.74
  • Y
    Yahoo Finance Insights
    Amicus Therapeutics reached a 52 Week low at 6.91
  • Y
    Yahoo Finance Insights
    Amicus Therapeutics reached a 52 Week low at 6.38
  • P
    Padraig
    WOW what volume!! 10 blocks for 4.27 million shares.
  • Y
    Yahoo Finance Insights
    Amicus Therapeutics reached a 52 Week low at 6.59
  • Y
    Yahoo Finance Insights
    Amicus Therapeutics reached a 52 Week low at 7.36
  • C
    Charlie
    haven't the directors fired JC, or at least stop him from selling exercised option shares, he;s making millions and sleeping life away
    Bearish
  • Y
    Yahoo Finance Insights
    Amicus Therapeutics reached a 52 Week low at 7.52
  • P
    Padraig
    Perceptive Advisors Master Fund just increased shares by 887,000 on 2/28 @ 8.11
    and 3/01 209,000 @ 8.24

    Now own 9.7%
  • N
    No Way Out
    As Yogi Berra said, it is deja vu all over again. FOLD's Migalistat went through the same situation before getting approval. The clinical trial for Migalistat had several cohorts, divided by disease severity/progression and the results for all but one cohort were indisputable and statistically significant, but for the patients with moderate/less-severe disease, the results were not - not because the drug didn't work, but because trying to tease out a difference in kidney function (eGFR measurements) for those with moderate disease didn't work - those with severe disease showed definitive improvement in the measurement, as well as all the other biological endpoints. Close to 100% of the patients that went through the Migalistat trial and switched from the ERT treatme chose to stay on Migalistat in the extension phase of the trial. Sound familiar? Just like the current situation, the "market" couldn't get past a missed p-value and the stock went from $15 to $5, before Migalistat was approved. It was a buying opportunity then and it is a buying opportunity now!
  • R
    Richard
    Per CEO statement from Sanofi and Novartis, it will take minimum 18 months to come up with Corona vaccine. Huge sell off in the market is nothing but temporarily get rid of risky assets by big asset managers. This Coronavirus may has little impact on 1st and 2nd qtr earnings but fundamentals of overall long term global growth outlook has not shifted. Fold completed and exceeded patient enrollment in the global phase III PROPEL study for Pompe disease. Fold plans to apply for and initiate a rolling submission of the Biologics License Application (BLA) for AT-GAA in late-onset Pompe disease and complete the final submission in the first half of 2021. Further, the company has two gene-therapy programs in the pipeline for two different types of Batten disease. Fold has exclusive worldwide rights to Penn’s next-generation gene therapy technologies for a majority of lysosomal disorders and 12 additional rare diseases, including Rett Syndrome, Angelman Syndrome, Myotonic Dystrophy and selected other muscular dystrophies. Fold has partnerships with Catalent Biologics and Thermo Fisher for clinical and commercial gene-therapy manufacturing. Brammer Bio, a part of Thermo Fisher, will assist Amicus’ gene therapy programs in CLN6 and additional forms of Batten disease with clinical and commercial-scale capabilities. Having all this positive news this stock is too cheap. Strong buy and hold in every dip in the market.
  • E
    End Game
    $NVAX conversation
    Going to bring the new Board Member to the focus. Personally, what is the value to the comapny. As an investor we have no say, we really don't. But we can try to understand if there's a value for anything that is done that affects or effects our investments.

    So for Margaret G. McGlynn, R. Ph.

    From public records here's what I"ve found and my opine,

    1983 -2009 26 yrs Merck marketing,sales and managed care roles
    2005-2009 President Global Vaccines and Infectious diseases, Merck and
    2009 Amicus Theraputics Board for Air Products and Chemicals, mational Industrial Advisory Committee for Buffalo School of Pharmacy and a member of the Global Alliance for Vaccine Immunization (GAVI) Board

    GAVI
    Geneva, 7 August 2020 – A new landmark collaboration between SII, the world’s largest vaccine manufacturer by volume, Gavi and the Bill & Melinda Gates Foundation will accelerate the manufacture and delivery of up to 100 million doses of COVID-19 vaccines for low- and middle-income countries (LMICs) as part of the Gavi COVAX AMC, a mechanism within the COVAX Facility.

    Period between 2009 and 2016 International AIDS Vaccine Initiative
    2016 HCU Network America Non-profit
    Current Vertex Pharm and Novavax Boards

    She recieved 7700 shares/$140 persh 1,078,000

    Current public assets
    $FOLD 27,919 shares = $615,893
    $VRTX 877 shares = $196,448
    $NVAX 7700 = $885,500

    My personal opinion,
    The most recent expereince is down the Low/Middle low income countries through GAVI and the Non-Profits she has either started or been part of. Non-profits I hope is where we aren;t going to be concentrating the NVAX efforts. I"ve done a few jobs for non-profits. Very tough budget minded people. Her last Merck experience was 2009, 11 years ago That's a far stretch for reaching back for an M&A attempt by Merk. For the last 4 years, 2005-2009 she was the President global vaccines and infectious disease.

    I hope we see the real value her. A real M&A expert, or gov't FDA expert of getting FDA approvals to help the company get past this and to get the nanoFlu and RSV through the processes.
  • W
    William
    I Have a Few Questions About Fold
    As a new investor in FOLD today, maybe some of you long time followers of this company can answer a few questions about the company for me. I bought in @ $14.70 after hours.

    1. Are these phase III trial results good enough to get a FDA approval for AT-GAA?

    2. If approved will Amicus sell it for around the same $300,000 per year price as Lumizyme?

    3. Does AT-GAA have any advantages over Lumizyme?

    4. In the overall scheme of things, how important to Amicus is FDA approval of AT-GAA?

    5. Is the almost $6 drop after hours from where it was trading a few days ago justified?
  • d
    dcaf7
    I think, it is good news for FOLD, "it failed to demonstrate superiority".

    Sanofi enzyme replacement therapy shows mixed results in Pompe study

    Jun. 16, 2020 8:24 AM ET|About: Sanofi (SNY)|By: Douglas W. House, SA News Editor
    Sanofi (NASDAQ:SNY) announces positive results from a Phase 3 clinical trial, COMET, evaluating avalglucosidase alfa, an enzyme replacement therapy, in patients with late-onset Pompe disease, an inherited disorder characterized by the buildup of glycogen in the body's cells due to the dysfunction of a certain enzyme.

    The study met the primary endpoint demonstrating non-inferiority (no worse than) to alglucosidase alfa (Lumizyme) as measured by the change in respiratory function but it failed to demonstrate superiority, the other primary objective.

    Since superiority was not shown, statistical testing of the secondary endpoints was not done.
  • C
    Charlie
    JC has ruined the company,then gets paid a fortune exercising then selling ,great gimmick
    Neutral
  • m
    mr
    Approved ! Congrats all Longs !
Advertisement
Advertisement